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A subset of colorectal cancer shows significant accu-
mulation of aberrant promoter methylation. Previ-
ously, we developed two groups of methylation mark-
ers that classified colorectal cancer into three
epigenotypes: i) high-, ii) intermediate-, and iii) low-
methylation epigenotypes. High-methylation epig-
enotype, with methylation of both group 1 and group
2 markers, correlates to BRAF-mutation(). Interme-
diate-methylation epigenotype, with methylation of
group 2 markers, but not group 1, correlates to KRAS-
mutation(). To gain insight into epigenotype devel-
opment in colorectal carcinogenesis, especially inter-
mediate-methylation epigenotype and its correlation
to KRAS-mutation() in adenoma, we analyzed meth-
ylation levels of group 1 and group 2 markers quan-
titatively by matrix assisted laser desorption ioniza-
tion-timeof flightmass spectrometry, in 51 adenomas, 13
aberrant crypt foci, and 26 normal mucosa samples,
and we compared them to 149 previously analyzed
colorectal cancer samples. Three serrated adenomas
were all BRAF-mutation(), showing great methyl-
ation of group 1 and group 2 markers, thus high-
methylation epigenotype. Forty-eight conventional ad-
enomas were not methylated in group 1 markers and
were classified into two clusters with higher and lower
methylation of group 2markers, thus into intermediate-
and low-methylation epigenotypes, respectively. Ade-
616noma with intermediate-methylation epigenotype cor-
related to KRAS-mutation(). Methylation levels of
group 2markers in adenomawere higher than aberrant
crypt foci and normal samples, but similar to cancer.
These data suggested that epigenotype development
occur at an earlier stage than carcinoma formation,
and already be completed at the adenoma stage. In-
termediate methylation epigenotype and its correla-
tion to KRAS-mutation() were developed in conven-
tional adenoma. (Am J Pathol 2012, 180:616–625; DOI:
10.1016/j.ajpath.2011.10.010)
Colorectal cancer arises as a consequence of genetic
alteration and epigenetic alteration.1 Gene mutations (eg,
KRAS, p53, and APC) are well-known genetic alterations
that occurred in colorectal cancer, which were demon-
strated in the model of “adenoma-carcinoma sequence”
by Bert Vogelstein.2 Epigenetic alteration, such as DNA
methylation or loss of imprinting, is also important in colo-
rectal carcinogenesis, and aberrant promoter methyl-
ation is a major epigenetic mechanism for gene silencing
to be involved in the initiation and progression of can-
cer.3,4 As for accumulation of aberrant methylation,
Toyota et al5 reported in 1999 that a subset of colorectal
cancer shows significantly frequent CpG island methyl-
ation [ie, the so-called CpG island methylator phenotype
(CIMP)]. CIMP colorectal cancer significantly correlates
to microsatellite instability and BRAF mutation.6
Colorectal adenoma is known as a precursor lesion of
colorectal cancer. Serrated adenomas were reported to
show CIMP and frequent BRAF mutation, and DNA
methylation was thus considered to be an early event in
the serrated pathway, which explains carcinogenesis
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AJP February 2012, Vol. 180, No. 2from serrated adenoma to colorectal cancer with micro-
satellite instability.7,8 Adenomas without serrated fea-
tures (nonserrated adenomas) were classified as con-
ventional adenomas, which correspond to tubular,
tubulovillous, and villous adenomas.9 Existence of meth-
ylation phenotype in the conventional adenomas and its
correlation to KRAS mutation were largely unknown.
In our previous study, we epigenotyped colorectal
cancer by the two-way hierarchical clustering method
Figure 1. Oncogene mutation statuses in aberrant crypt foci (ACF) and ad
detected by genotyping assay using matrix assisted laser desorption ioniz
confirmed to be more than 40% (H&E staining), so that the peak for a mutant
height for wild-type allele. B: Summary of oncogene mutation frequency, in which a
11 of 48 conventional adenoma samples were KRAS-mutation(). Conventional, cousing highly quantitative DNA methylation data, and we
identified three clusters of colorectal cancer with distinct
methylation epigenotypes.10 High-methylation epigeno-
type (HME) correlated to BRAF-mutation() and micro-
satellite instability,10 as CIMP was previously reported.6
In microsatellite stable colorectal cancer, intermediate
methylation epigenotype (IME) correlated to KRAS-muta-
tion() and a lack of BRAF mutation, and low methylation
epigenotype (LME) correlated to lack of BRAF/KRAS mu-
A: Representative results of H&E staining (200) and oncogene mutations
e of flight-mass spectrometry. The content of ACF or adenoma cells was
rrow) would be high enough, presumably higher than a quarter of the peak
enoma.
ation-tim
allele (all of the three serrated adenoma samples were BRAF-mutation( ), whereas
nventional adenoma; HE, H&E; SA, serrated adenoma.
n start s
618 Yagi et al
AJP February 2012, Vol. 180, No. 2tation. These three epigenotypes and their strong corre-
lation to different oncogene mutations suggested distinct
molecular genesis of colorectal cancer.10
The two-way hierarchical clustering in our study also
classified DNA methylation markers into two groups (ie,
group 1 and group 2 markers).10,11 Group 1 markers
included most of the previously established CIMP mark-
ers5,6,12 and were characterized to be methylated spe-
cifically in HME/CIMP colorectal cancer. Group 2 mark-
ers are methylated in both HME and IME, but not in LME.
Therefore, colorectal cancer methylated in group 1 mark-
ers (and also inevitably group 2 markers) is regarded as
HME, and colorectal cancer without group 1 marker
methylation (but methylated in group 2 markers) is re-
garded as IME.11
Whereas BRAF mutation and CIMP marker methylation
were reported in serrated adenomas,7,8 methylation ac-
cumulation in conventional adenomas, or association be-
tween the methylation and KRAS mutation, has not been
clarified yet. We therefore analyzed methylation status in
48 conventional adenomas using 15 group 2 markers, as
Table 1. Methylation Marker Genes and Primer Sequences
Gene
symbols
Primer sequen
Forward
ADAMTS1 5=-GTTTTTTGGGGTTTTAATGT-3= 5=-C
COL4A2 5=-TAGYGTAGGATGAGGGAGGT-3= 5=-C
DFNA5 5=-GGTTAGATTTTTTAGAAGTTTTAGA-3= 5=-A
EFEMP1 5=-TAGGAGTTGGTTAGAAGTTGG-3= 5=-A
ELMO1 5=-AATGTGTTTTTGGTTAGTAGGAG-3= 5=-A
FBN2 5=-GGATATTGGAAAGTTGTAAAAG-3= 5=-C
HAND1 5=-GGGAAAGTTTATAGTGGAGAGAG-3= 5=-C
IGFBP3 5=-GTTTTTTGTTTGGATTTTATAGTT-3= 5=-A
IGFBP7 5=-GAGAAGGTTATTATTTAGGTTAGTAA-3= 5=-A
LOX 5=-TGGTATTGTTTGGTGGAGAT-3= 5=-A
MINT31 5=-GGTGGTGTAGTTTTAGGAGAG-3= 5=-A
NEUROG1 5=-AGTTTGGGGTTGTTATTTTGT-3= 5=-C
RUNX3 5=-GAGTAGTGGGGATGGGAGGT-3= 5=-C
SFRP1 5=-GTTTTGTTTTTTAAGGGGTGTTGAG-3= 5=-A
STOX2 5=-GGTTTTAGGTTGGGGTAGTT-3= 5=-G
THBD 5=-TAGTTTTTTTTATTAGGATTTTTTT-3= 5=-C
TSPYL5 5=-GGAAGAGATGAAATGGTAGTAT-3= 5=-T
UCHL1 5=-YGGTAGAAATAGTTTAGGGAAG-3= 5=-T
Positions of 5= end of the primers were shown, regarding transcriptio
Table 2. Primer Sequences Used for Mutation Analysis
Mutation sites Primer sequenc
KRAS_34
Forward 5=-ACGTTGGATGAGGCCTGCTG
Reverse 5=-ACGTTGGATGTAGCTGTATC
KRAS_38
Forward 5=-ACGTTGGATGAGGCCTGCTG
Reverse 5=-ACGTTGGATGTAGCTGTATC
KRAS_35
Forward 5=-ACGTTGGATGAGGCCTGCTG
Reverse 5=-ACGTTGGATGTAGCTGTATC
BRAF_1799
Forward 5=-ACGTTGGATGTCTTCATGAA
Reverse 5=-ACGTTGGATGTTCAAACTGATGGGAwell as three group 1 markers, by bisulfite-PCR-based
highly quantitative method, matrix assisted laser desorp-
tion ionization-time of flight mass spectrometry (MassAR-
RAY). Herein we report that epigenotype development is
earlier than cancer stage and already completed at ad-
enoma stage, and that IME and its correlation to KRAS
mutation are developed in conventional adenoma.
Materials and Methods
Clinical Samples
Clinical colorectal adenoma, aberrant crypt foci, and nor-
mal mucosa samples were obtained from the patients
who underwent endoscopic examination at Yokohama
City University Hospital with written informed consents,
and kept at 80°C until use. Colorectal cancer samples
were obtained from the patients who underwent surgery
at Saitama Cancer Center, with written informed con-
sents, and their DNA was extracted in our previous
Positions
(TSS  1)
GroupReverse
Forward
5=
Reverse
5=
CACCACTAACTCCTC-3= 440 647 2
ATACAAACTAAAACTACAC-3= 302 551 2
CACTCCACTATAAATAAC-3= 170 435 2
AATTCTCTTTTATCTTATCA-3= 167 53 2
CTCTACCTCTATCCTATACC-3= 89 61 2
TCTCTCTTACTAAC-3= 176 13 2
ATCACTCCTTAAAAATC-3= 1216 950 2
CACCAACAAAATCAAC-3= 38 189 2
AACTCTTTCCCTCC-3= 455 651 2
AACAAACTAAACACCTA-3= 128 453 1
TCCCCAACATCTAC-3= NA NA 1
AAATCCTAAAACCAATC-3= 42 160 2
AAAATCATTCCTACAAAAC-3= 771 902 1
ACTCCRAAAACTACAAAAC-3= 186 22 2
AGGTTGGGGTAGTT-3= 291 568 2
CATATTACCCAAAC-3= 99 169 2
ACACRCTATAACCCTA-3= 183 85 2
ATACACTCAAAAAACAC-3= 234 51 2
ite as  1 bp. NA, not applicable, because MINT31 is not a gene.
Extend primers
GACTG-3= 5=-ACTCTTGCCTACGCCAC-3=
GGCAC-3=
GACTG-3= 5=-AGGCACTCTTGCCTACG-3=
GGCAC-3=
GACTG-3= 5=-CACTCTTGCCTACGCCA-3=
GGCAC-3=
CACAG-3= 5=-CCCACTCCATCGAGATTTC-3=ces
TCCRA
RCCTT
ATCCA
CRACT
AATAA
CRCCC
AAATC
AACAA
CTACC
AACTC
ACACT
TTAAA
CRTTA
CACTA
GTTTT
CCAAA
CAAAA
ACTCCes
AAAAT
GTCAA
AAAAT
GTCAA
AAAAT
GTCAA
GACCT
CCCAC-3=
Epigenotypes of Colorectal Adenoma 619
AJP February 2012, Vol. 180, No. 2study.10 All of the aberrant crypt foci and adenoma sam-
ples were microscopically examined for determination of
its lesion contents by two independent pathologists.
Then, 51 adenoma (2 traditional serrated adenomas, 1
sessile serrated adenoma, and 48 conventional adeno-
mas) and 13 aberrant crypt foci samples that contained
at least 40% of lesion cells, were prepared (Figure 1A).
We analyzed methylation and oncogene mutation sta-
tuses of 48 conventional adenoma samples, and com-
pared them with 3 serrated adenomas, 13 aberrant crypt
foci, 26 normal mucosa samples, and 149 previously
analyzed colorectal cancers.10 DNA of clinical samples
was extracted using QIAamp DNA Micro Kit (QIAGEN,
Hilden, Germany). This study was certified by the Ethics
Committee in Tokyo University, Yokohama City University
and Saitama Cancer Center.
Bisulfite Treatment
Bisulfite conversion of genomic DNA was performed as
previously described.13 After sonication of genomic DNA in
30 seconds by Bioruptor (Cosmobio Co. Ltd., Tokyo, Ja-
pan), 500 ng of DNA was denatured in 0.3 N NaOH, and
then subjected to 15 cycles of 30 seconds at 95°C and
15-minute incubation in 3.6 M sodium bisulfite and 0.6
mmol/L hydroquinone at 50°C. The samples were desalted
with the Wizard DNA Clean-Up system (Promega, Madison,
WI), desulfonated in 0.3 N NaOH at room temperature for 5
minutes, and then purified by ethanol precipitation. Finally,
genomic DNA was diluted by 40 L of distilled water.
Methylation Analysis
Quantitative methylation analysis was performed using
MALDI-TOF mass spectrometry (MassARRAY, Seque-
nom, San Diego, CA).10,14 Bisulfite-treated DNA was am-
plified by PCR, the PCR product was transcribed by in
vitro transcription, and the RNA was cleaved by RNaseA.
Unmethylated cytidine was converted to Uridine by bisul-
fite treatment [ie, thymidine in the PCR product], and
finally adenosine in the in vitro transcription product.
Methylated cytidine was not converted (ie, cytidine in the
PCR product), and finally guanosine in the in vitro tran-
scription product. Since RNaseA cleaves RNA at the 3=
site of both thymidine and cytidine, thytidine-specific
cleavage was possible by containing deoxycytidine in-
stead of cytidine in the in vitro transcription mixture. Meth-
ylation status was determined by mass difference be-
tween adenine and guanine in a cleaved RNA product.
Quantitative methylation was calculated for each cleaved
product. This analytic unit containing several CpG sites in
a cleaved product was called the “CpG unit.”
Primers were designed in the previous study10 to in-
clude no CpG site or only one CpG site in 5= regions of
primers, which is listed in Table 1. Three group 1 markers
were randomly chosen and used, because three were
enough to confirm hypermethylation status of group 1
markers (CIMP markers) in serrated adenoma. As many
as 15 group 2 markers showing a variety of average
methylation levels10 were chosen, because investigation
on IME existence in conventional adenomas was the ma-jor purpose of this study, and such number of markers
were necessary for hierarchical clustering and demon-
stration of methylation development in precursor lesions.
All of the primers were validated for their accuracy for
quantitative analysis by calculating correlation coefficient
(r2) of the standard curve using methylation control sam-
ples (0, 25, 50, 75, and 100% methylation) at each CpG
Figure 2. Methylation frequency of 18 markers in adenoma samples. A:
Methylation was regarded as () when methylation rate by quantitative
analysis was 35% (closed box). Gray box indicates no results in matrix
assisted laser desorption ionization-time of flight-mass spectrometry. Sam-
ples were sorted from top to bottom in descending order for the number of
methylated markers. Markers were sorted from left to right in ascending order
for the number of methylated samples. The three most frequently methylated
samples were serrated adenoma (SA); each sample showed methylation in
two of the three group-1 markers, as well as very frequent methylation of
group-2 markers (93 to 100%). In 48 conventional adenoma samples, group-1
markers were hardly methylated, and the methylation of group-2 markers
varied (0% to 93%). KRAS mutation was enriched upward in the panel, and
there was significant correlation between frequent methylation of group-2
markers and KRAS mutation (P  2.7  103, Wilcoxon rank sum test). SSA,
sessile serrated adenoma; TSA, traditional serrated adenoma. B: Comparison
of number of methylated markers. The three BRAF-mutation() serrated
adenoma samples showed markedly frequent methylation. KRAS-muta-
tion() adenomas showed significantly frequent methylation of group-2
markers (9.7 3.6 markers) than oncogene-mutation(-) adenomas (6.0 3.1
markers; *P  7.8  103).
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pairs whose amplicon contained three or more CpG units
with R2  0.9 were used in this study.
Mutation Analysis
Mutation at BRAF 1799 and KRAS 34, 35, and 38 were
analyzed by genotyping assay on MassARRAY plat-
form.15 First, PCR amplification primers and a post-
PCR extension primer were designed using MassAR-
RAY Assay Design 3.0 software (Sequenom), as listed
in Table 2. BRAF 1799 and KRAS 38 mutation were
analyzed in a single reaction by multiplex PCR. The
PCR amplification was performed in 5 L volumes con-
Table 3. Clinical and Molecular Characteristics of Adenoma acco
Clinical or molecular features HME
Number of samples 3 (6%) 1
Sex
Male 2 (66%) 1
Female 1 (33%)
Age
Mean  SD 72  11.1 6
Tumor size
Average (mm) SD 13.3 2.9 1
10 mm 2 (66%)
10 mm 1 (33%)
Tumor location
Proximal 1 (33%)
Distal 2 (67%) 1
BRAF mutation
() 3 (100%)
() 0 (0%) 1
KRAS mutation
() 0 (0%)
() 3 (100%)
Proximal location is the cecum to the transverse colon. Distal location
*P value between IME and LME  0.05 (calculated by Fisher’s exact test, ex
HME, high methylation epigenotype; IME, intermediate methylation epigenotytaining 0.5 units of Taq polymerase, 5 ng of genomic
DNA, 0.5 pmol of PCR primer, and 2.5 nmol of deoxy-
ribonucleotide triphosphates. PCR reactions were cy-
cled at 94°C for 15 minutes, followed by 45 cycles of
94°C for 20 seconds, 56°C for 30 seconds, and 72°C
for 1 minute. Shrimp alkaline phosphatase treatment
was performed at 37°C for 20 minutes and 85°C for 5
minutes. Post-PCR primer extension was performed
using 5.6 pmol of extension primer. Extension reaction
were cycled at 94°C for 30 seconds, followed by 40
cycles of 94°C for 5 seconds, 5 cycles of 52°C for 5
seconds, and 80°C for 5 seconds, and 72°C for 3
minutes. Reaction products were transferred to a
SpectroCHIP (Sequenom), and mass difference was
Figure 3. Unsupervised hierarchical clustering
of 48 conventional adenoma samples. Markers
in black indicate group 2 markers, and markers
in green indicate group 1 markers. Conventional
adenoma samples were classified into two clus-
ters: the right cluster of 13 cases (yellow) shows
higher methylation of group 2 markers and sig-
nificantly high frequency of KRAS mutation (P
4.7  104, Fisher’s exact test), which was con-
sidered to be intermediate methylation epigeno-
type (IME); the left cluster of 34 cases (red)
shows less or no methylation of group 2 markers
and less frequency of KRASmutation, which was
considered to be low methylation epigenotype
(LME). One case (pale blue) was considered as
an outlier. As for the markers, group 1 markers
were hardly methylated and were grouped into
one cluster (green).
o Three Epigenotypes
LME P value (IME versus LME)
) 34 (68%)
) 23 (68%) 0.14
) 11 (32%)
5.6 66.9  10.5 0.93
5.9 9.7 4.2 0.043*
) 10 (29%) 0.18
) 24 (71%)
) 14 (41%) 0.32
) 20 (59%)
) 0 (0%) 1
%) 34 (100%)
) 3 (9%) 4.7 104*
) 31 (91%)
descending colon to the rectum.rding t
IME
3 (26%
2 (92%
1 (8%
6.7 
3.6
7 (54%
6 (46%
3 (23%
0 (77%
0 (0%
3 (100
8 (62%
5 (38%
is the
cept age and tumor size by Student’s t-test).
pe; LME, low methylation epigenotype; SD, standard deviation.
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the extended base at the possible mutation site.
Statistical Analysis
Correlation between epigenotypes and clinicopathologi-
cal factors, except age and tumor size were analyzed by
Fisher’s exact test. Age and tumor size were analyzed by
Student’s t-test. Unsupervised two-way hierarchical clus-
tering was performed based on Euclid distance correla-
tion and average linkage clustering algorithm in sample
and marker directions using GeneSpring 7.3.1 software
(Agilent Technology, Santa Clara, CA).
Results
Mutation of Adenoma and Aberrant Crypt Foci
We analyzed mutation statuses of BRAF and KRAS in 51
colorectal adenomas (3 serrated and 48 conventional
adenomas) and 13 aberrant crypt foci, using MALDI-TOF
mass spectrometry (Figure 1). All of the three serrated
adenoma samples (including two traditional and one ses-
sile serrated adenomas) showed BRAF mutation (100%)
and no KRAS mutation (0%). Among 48 conventional
adenoma samples, 11 showed KRASmutation (23%) and
none showed BRAF mutation (0%). In 13 aberrant crypt
foci, 5 showed KRAS mutation (38%) and none showed
BRAF mutation (0%).
Methylation Rate of Analyzed Samples
Among group 1 and group 2 markers we established in
the previous study,10 we analyzed methylation rates of
three group 1 markers and 15 group 2 markers in ade-
noma, aberrant crypt foci, and normal mucosa samples.
Methylation frequency of 18 markers in adenoma sam-
ples was summarized in Figure 2A. Three top-ranking
samples with the most frequent methylation were ser-
rated adenomas; each sample showed methylation in two
of the three group 1 markers as well as very frequent
methylation of group 2 markers, ranging 93 to 100%. The
three serrated adenoma samples were thus considered
as HME, and all of the three showed BRAF mutation
whereas none of conventional adenoma showed BRAF
mutation (P  4.8  105) (Figure 1). In conventional
adenoma, group 1 markers were hardly methylated, sug-
gesting that there was no HME case. Group 2 marker
methylation varied from 0% to 93% (Figure 2A). There
was significant correlation between frequent methylation
of group 2 markers and KRAS mutation (P  2.7  103,
Wilcoxon rank sum test).
When number of methylation markers and oncogene
mutation status were compared, the three BRAF-muta-
tion() serrated adenoma samples showed markedly
frequent methylation (Figure 2B). KRAS-mutation() ad-
enoma showed significantly frequent methylation of
group 2 markers (9.7  3.6 markers) than BRAF/KRAS-
mutation() adenoma (6.0  3.1 markers, P  7.8 
103, Student’s t-test).Hierarchical Clustering of Conventional
Colorectal Adenoma
To analyze whether conventional adenoma can be
classified into some clusters using DNA methylation
information, two-way unsupervised hierarchical cluster-
ing method was applied in the analysis using quantitative
methylation data (Figure 3). Conventional adenoma was
classified into two major clusters; a cluster with higher
methylation rate of group 2 markers was considered as
IME, and the other with lower methylation rate was LME.
IME adenoma showed significant correlation to KRAS-
mutation() (P  4.7  104, Fisher’s exact test) (Figure
3). As for other clinicopathological factors, adenoma size
in IME was significantly larger than LME (P  0.043,
Figure 4. Comparison of methylation rates in different epigenotypes. Meth-
ylation levels were shown by average methylation rate  SE. A: Methylation
rate of group 1 markers in three serrated adenomas (SA) (gray box), inter-
mediate methylation epigenotype (IME) conventional adenomas (open box),
and low methylation epigenotype (LME) conventional adenoma (hatched
box). The three serrated adenomas showed higher methylation rate com-
pared to IME and LME adenomas. These three BRAF-mutation() serrated
adenoma samples were thus considered to be high methylation epigenotype
(HME). SSA, sessile serrated adenoma; TSA, traditional serrated adenoma. B:
Methylation rate of group 2 markers. IME adenoma samples showed a higher
methylation rate in all of the group 2 markers compared to LME. Group 2
markers had been classified into HIL and HIL types in a previous
study of colorectal cancer,10,11 whereas similar methylation patterns were
confirmed in adenoma. For example, ELMO1, STOX2, NEUROG1, HAND1,
and IGFBP7 were included in HIL type, and THBD, FBN2, ADAMTS1,
EFEMP2, and COL4A2 in H  IL type. C: Two-step marker panel. Epig-
enotypes can be determined using two panels of markers, without hierar-
chical clustering method. The first panel containing three group 1 markers
extracted cases with methylation of2 markers as HME. The remaining cases
with methylation of 1 marker undergo the second panel containing three
group 2 markers, and were classified into cases with methylation of 2
markers as IME, and cases with methylation of 1 marker as LME. Among 50
cases, there were 47 (94%) that were accurately determined.
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difference (P  0.31, Fisher’s exact test) (Table 3).
Comparison of Methylation Levels among
Different Epigenotypes
The methylation rates of markers were compared accord-
ing to epigenotypes (Figure 4). In group 1 markers, the
three serrated adenoma samples showed higher methyl-
ation rate than IME and LME adenomas, confirming that
the serrated adenoma is HME (Figure 4A). In most group
2 markers, the methylation rate was generally highest in
HME, lowest in LME, and at an intermediate level in IME
(Figure 4B). We had classified group 2 markers into
HIL and HIL types in a previous study of colorec-
tal cancer,10,11 whereas similar methylation patterns were
confirmed in adenoma (eg, ELMO1, STOX2, NEUROG1,
HAND1, and IGFBP7 as HIL type, and THBD, FBN2,
ADAMTS, and COL4A2 as HIL type.
Development of Two-Step Marker Panel
In the previous analysis of colorectal cancer, we devel-
oped a two-step panel method to classify HME, IME, and
LME easily without hierarchical clustering.10 Because
group 1 markers are methylated specifically in HME, and
group 2 markers are methylated commonly in HME and
IME, HME cases should be extracted as frequently meth-
ylated samples using the first panel containing three to
five group 1 markers. The remaining cases could be
divided into IME and LME by the second panel contain-
ing three to five group 2 markers.11 Here we developed a
two-step marker panel in the similar manner, with 94%
accuracy (Figure 4C). The first panel containing three
group 1 markers (LOX, MINT31, and RUNX3) can extract
three cases with methylation of 2 markers as HME (3/3;
100% accuracy). The remaining 47 cases undergo the
second panel containing three group 2 markers (ELMO1,
THBD, and NEUROG1). There were 47 cases that were
divided into 13 cases with methylation of 2 markers as
IME (12/13; 92% accuracy), and 34 cases with methyl-
Figure 5. Comparison of average methylation rate between adenoma and c
compared among conventional adenoma (ad) (n  48), stage II cancer (II) (
in intermediate methylation epigenotype (IME) (A) and low methylation epi
(n  21), IME stage III cancer (n  16), and IME stage IV cancer (n  26).
and carcinoma stages. All of the 15 group-2 markers showed high methylati
among adenoma and three cancer stages in any marker (Student’s t-test). B:
cancer (n 27) and LME stage IV cancer (n 26). Methylation rates were generally lo
adenoma and three cancer stages in all of the marker except COL4A2, which showeation of 1 marker as LME (32/34; 94% accuracy); this is
an easier and useful decision method than an 18 gene
panel (Figure 2A) and hierarchical clustering (Figure 3).
Methylation of Adenoma and Carcinoma
It was shown that methylation is accumulated enough at
the stage of adenoma to develop epigenotype with cor-
relation to oncogene mutation. To analyze whether there
is any more increase of methylation rate from colorectal
adenoma to cancer, average methylation rate was com-
pared between adenoma and cancer samples (Figure 5).
In IME adenoma and cancer, there was no difference of
methylation rate in any markers from adenoma, to stage II
CRC, stage III CRC, and stage IV CRC (Figure 5A). In
LME, although COL4A2 showed a slight but significant
increase of methylation rate from adenoma to cancer,
there was no difference of methylation rate in any other
markers (Figure 5B). It was suggested that accumulation
of the aberrant promoter methylation was mostly com-
pleted at adenoma stage already, at least for the ana-
lyzed markers.
Comparison of Aberrant Crypt Foci and
Adenoma
To analyze whether there is any difference of methylation
rate in adenoma and any other colorectal lesion with
oncogene mutation, the average methylation rate was
compared among normal colorectal mucosa, aberrant
crypt foci, and adenoma samples (Figure 6). All of the 15
group 2 markers showed significant methylation increase
in adenoma compared to normal colorectal mucosa, and
also 12 of 15 group 2 markers in adenoma compared to
aberrant crypt foci, whereas only SFRP1 among 15 group
2 markers showed significant methylation difference be-
tween normal colorectal mucosa and aberrant crypt foci
(P 0.01; Student’s t-test) (Figure 6A). Because aberrant
crypt foci showed low methylation levels and all of them
were regarded as LME by the established two-step panel
(Figure 4C), the aberrant crypt foci could not be divided
ethylation levels were shown by average methylation rate  SE, and were
stage III cancer (III) (n  43), and stage IV cancer (IV) (n  52), separately
e (LME) (B). A: Comparison of IME adenoma (n  13), IME stage II cancer
e three group-1 markers kept low methylation levels throughout adenoma
in adenoma at similar levels to cancer. There was no significant difference
ison of LME adenoma (n  34), LME stage II cancer (n  14), LME stage IIIancer. M
n  35),
genotyp
All of th
on rates
Comparwer than IME. There was no significant difference of methylation rate among
d methylation increase from adenoma to cancer (*P  0.01, Student’s t-test).
Epigenotypes of Colorectal Adenoma 623
AJP February 2012, Vol. 180, No. 2into IME and LME, so it was classified into KRAS-muta-
tion() and KRAS-mutation(-) instead (Figure 6, B and C).
Also in comparison of KRAS-mutation() lesions, only
ADAMTS1 among 15 group 2 markers did show signifi-
cant methylation difference between normal colorectal
mucosa and aberrant crypt foci, but 12 of 15 group 2
markers showed significant difference between normal
colorectal mucosa and adenoma, and 7 markers be-
tween aberrant crypt foci and adenoma (P  0.01;
Student’s t-test) (Figure 6B). In comparison of KRAS-
Figure 6. Comparison of average methylation rates between adenoma and
aberrant crypt foci. Methylation levels were shown by average methylation
rate SE. A: Normal colorectal mucosa (n 26), all of the aberrant crypt foci
(ACF) (ACF_all, n  13) and all of the conventional adenoma (Ad) (Ad_all,
n  48) were compared. All of the 15 group-2 markers showed significant
difference between normal colorectal mucosa and adenoma (*P  0.01,
Student’s t-test), and 12 of 15 group-2 markers between aberrant crypt foci
and adenoma (†P  0.01), whereas only SFRP1 among 15 group 2 markers
showed a significant methylation difference between normal colorectal mu-
cosa and aberrant crypt foci (‡P  0.01). B: Normal colorectal mucosa (n 
26), aberrant crypt foci with KRAS mutation (n  5), and conventional
adenoma with KRAS mutation (n  11) were compared. Again, higher
methylation of group-2 markers in adenoma was generally detected rather
than normal mucosa or aberrant crypt foci. There were 12 of 15 group-2
markers that showed a significant difference between normal colorectal
mucosa and adenoma (*P  0.01), and 7 of 15 markers that showed a
significant difference between aberrant crypt foci and adenoma (†P  0.01),
whereas only ADAMTS1 among 15 group-2 markers showed a significant
methylation difference between normal colorectal mucosa and aberrant crypt
foci (‡P  0.01). C: Normal colorectal mucosa (n  26), aberrant crypt foci
without KRAS mutation (n  8), and conventional adenoma without KRAS
mutation (n 37) were compared. Higher methylation of group-2 markers in
adenoma was detected rather than normal mucosa or aberrant crypt foci.
There were 13 of 15 group-2 markers that showed a significant difference
between normal colorectal mucosa and adenoma (*P  0.01), and 9 of 15
markers showed a significant difference between aberrant crypt foci and
adenoma (†P  0.01), whereas no markers showed a significant methylation
difference between normal colorectal mucosa and aberrant crypt foci.mutation(-) lesions, no markers showed significantmethylation difference between normal colorectal mu-
cosa and aberrant crypt foci, but 13 of 15 group 2
markers showed significant difference between normal
colorectal mucosa and adenoma, and 9 markers be-
tween aberrant crypt foci and adenoma (P  0.01;
Student’s t-test) (Figure 6C).
Discussion
To gain insight into epigenotype development in colorec-
tal carcinogenesis, especially the existence of IME and
its correlation to KRAS mutation in colorectal adenoma,
we performed a quantitative methylation analysis of
group 1 and group 2 markers in 48 conventional adeno-
mas, and compared them to 3 serrated adenomas, 149
colorectal cancers, 13 aberrant crypt foci, and 26 normal
samples. The serrated adenoma showed HME and
BRAF-mutation(), the conventional adenoma was clas-
sified into IME and LME, and the IME showed significant
correlation to KRASmutation(). Epigenotype was shown
to be developed earlier than cancer progression, and it is
already completed at the adenoma stage.
Whereas the conventional adenoma had been consid-
ered as the precursor lesion of colorectal cancer, hyper-
plastic polyps had been deemed to have no malignant
potential.16 In 1990, Longacre and Fenoglio-Preiser17 an-
alyzed a group of polyps with features similar to hyper-
plastic polyps and adenomas, and these unique lesions
with a serrated morphology were named “serrated ade-
noma.” It is now considered that serrated adenomas con-
sist of traditional serrated adenoma and sessile serrated
adenoma.9 Sessile serrated adenoma is known to share
common molecular features with sporadic microsatellite-
instable colorectal cancer including BRAF-mutation()
and CIMP, and is thus considered to be a precursor of
CIMP colorectal cancer.7–9,15,18 We confirmed that the
one sessile serrated adenoma in this study showed HME/
CIMP and BRAF-mutation(). In less common traditional
serrated adenoma,9 reported frequencies of BRAF muta-
tion varied from low frequency as 20% (1/5 cases) com-
pared to 75% (12/16) of sessile serrated adenoma,7 to
high frequency as 67% (2/3) compared to 78% (28/36) of
sessile serrated adenoma.15 There is also less known
regarding carcinoma arising in traditional serrated ade-
noma.9 In this study, the two traditional serrated adeno-
mas showed HME/CIMP and BRAF-mutation(), as with
the sessile serrated adenoma. Although the major pur-
pose of this study is analysis of conventional adenomas
and the sample size of serrated adenomas was as small
as three, analysis of more sessile and traditional serrated
adenoma samples would clarify epigenotypes and onco-
gene statuses within serrated adenomas.
On the other hand, any of the conventional adenoma
did not show HME or BRAF-mutation(). Instead, KRAS
mutation was frequently observed (23%) in conventional
adenoma. These frequencies are concordant with the
previous reports,19,20 however, it was not been previously
clarified whether there was any specific phenotype of
methylation accumulation or its association to KRAS-mu-
tation status in conventional adenoma. O’Brien et al20
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methylation-specific PCR and reported that methylation
level of serrated polyps is higher than conventional ade-
nomas, which is similar to our results of group 1 marker
methylation. Kim et al21 analyzed methylation status of
seven genes also by methylation-specific PCR and dis-
tinct gene-specific methylation profile was suggested be-
tween serrated polyps and tubular adenomas. Similar to
our results that IME adenomas were larger than LME
adenomas, Kakar et al22 reported that higher frequency
of methylation was associated with larger size of adeno-
mas. In these previous reports, however, any methylation
phenotype or its association to KRAS mutation within
conventional adenomas had not been identified. This
might perhaps be due to lack of suitable markers. Also,
methylation-specific PCR is not quantitative assay, and
quantitative methylation analysis is preferable for molec-
ular classification.23
By quantitative methylation analysis using both group
1 markers (CIMP markers) and group 2 markers that we
previously developed,10 we classified conventional ade-
noma into IME and LME through an unsupervised hierar-
chical clustering method. IME adenoma correlated sig-
nificantly to KRAS-mutation(), as well as IME colorectal
cancer.10 Moreover, there is no difference of methylation
levels between IME adenoma and IME cancer. These
indicated that the epigenotype development is already
completed at the adenoma stage. It might also be sug-
gested that conventional adenoma is a precursor of
IME and LME colorectal cancer, and that the epigeno-
types (IME or LME), which the tumor would show after
cancer progression, is already determined at the ade-
noma stage.
Aberrant crypt foci in colorectal mucosa are the earli-
est known neoplastic lesions with monoclonal cell expan-
sion.24–26 The cell expansions occur to a limited state,
despite the frequent mutation of KRAS, and they showed
significantly lower levels of methylation than KRAS-muta-
tion() adenoma. Analyzed aberrant crypt foci were not
numerous, although our data might suggest that methyl-
ation accumulation occurs during aberrant cell expan-
sion in adenoma formation. Considering that oncogene
mutation in normal cells could cause cellular growth ar-
rest, the so-called oncogene-induced senescence,27
perhaps methylation of group 2 marker genes in IME may
be a requested aberration for further cellular growth to
form KRAS-mutation() adenoma.
If methylation accumulation is completed at the ade-
noma stage, then there needs to be a cause for adenoma
to become malignant other than the methylation of ana-
lyzed group 2 markers. One possibility is that there might
be other group 2 genes that are not methylated in IME
adenoma but would be methylated in IME cancer to
cause malignant change. In the case of carcinogenesis for
HME, such a gene can be considered to be MLH1; other
group 1 genes are methylated, butMLH1 is not methylated
at the adenoma stage, andMLH1 is methylated in cancer to
cause microsatellite instability and mutator phenotype.28
Another possibility is that genetic or genomic alterations
can be the causes for adenomas to become malignant. In
sporadic colorectal cancer, microsatellite instability andchromosomal instability are well-characterized genetic
alterations, and these two pathways are exclusive.29 To
clarify genesis of malignant formation from colorectal ad-
enoma to cancer, further analyses should be performed,
including methylation of more genes and chromosomal
instability.
In this study, we found that IME and its correlation to
KRAS mutation are developed in conventional adenoma,
and that epigenotype development is already completed
at adenoma stage.
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